Assisted Reproductive Technology through Artificial Intelligence

By Sumona Bose

March 6, 2024

Introduction

Since the first successful in vitro fertilisation (IVF) birth in 1978, assisted reproductive technology (ART) has advanced, aiding over eight million infertile couples in conceiving. The intricate protocols of IVF involve critical decision-making points handled by clinicians and embryologists, blending evidence-based choices with subjective judgments, shaping ART as both science and art. Artificial intelligence (AI) offers a promising avenue for optimising ART processes like drug selection, cycle monitoring, and embryo selection. Could this be a beginning to a future of unbelievable progress in the field of reproductive health?

Personalising ART with Machine Learning

Customising ART based on individual factors like ovarian reserve, genetic variations, and ethnic disparities can significantly impact treatment success. Machine learning (ML) methods enable tailoring treatment regimens to patient subgroups, optimising ovarian response, and luteal phase support. The integration of ML algorithms into clinical decision support systems (CDSS) harnesses the potential of electronic health records, offering personalised and data-driven approaches to enhance ART outcomes. As shown in Figure 1, the procedures involving ART are intricate, demanding thorough supervision. Clinicians and embryologists bear the responsibility for numerous crucial decision junctures both before and throughout the treatment cycle. AI contributes to this complex process with its data analysis skills.

Figure 1: Potential targets for the application of artificial intelligence and ML methods during clinical and embryological steps in ART. The order and timings of the steps can differ depending on the ART protocol used.

Transparency and Trust in AI Applications

The adoption of AI in ART faces challenges related to trust and interpretability, especially with complex ‘black-box’ models. Transparency emerges as a crucial factor in AI systems to ensure clinicians’ confidence in decision-making tools. Efforts to enhance explainability in AI models, particularly in image-based analyses in embryology, aim to provide insights into model reliability, fairness, and trustworthiness, paving the way for more widespread and effective use of AI in reproductive healthcare.

Conclusion

The integration of AI technologies holds immense promise in ART, offering personalised, data-driven, and transparent solutions to enhance the success rates and safety of assisted reproduction procedures. The blend of science and art in ART, with its intricate protocols and subjective decision-making, sets the stage for AI to make significant advancements in this field.

Reference url

Recent Posts

toripalimab nasopharyngeal carcinoma
        

Toripalimab Evidence Journey in Cancer Care

🚀 How did toripalimab become the first immunotherapy approved in the U.S. for nasopharyngeal carcinoma?

The toripalimab evidence journey began with clinical trials in Asia. The JUPITER-02 trial showed toripalimab plus chemotherapy extended median progression-free survival (PFS) to 21.4 months versus 8.2 months with chemotherapy alone

#SyenzaNews #oncology #HealthcareInnovation

blood cancer treatments
        

NICE Breakthrough: Record Positive Recommendations for Blood Cancer Treatments in 2024

🚀 The National Institute for Health and Care Excellence (NICE) has made great strides in 2024, reporting a record number of positive recommendations for blood cancer therapies. This pivotal moment not only accelerates patient access to advanced treatments but also highlights the importance of precision medicine in oncology care.

Curious to learn how these advancements are reshaping the healthcare landscape and improving patient outcomes? Explore the full article for insights!

#SyenzaNews #oncology #HealthcareInnovation

Pembrolizumab Enfortumab therapy
              

Approval of Pembrolizumab Enfortumab Therapy: Insights on Efficacy, Costs, and Patient Eligibility

🔍 What does the recent decision by the German Federal Joint Committee mean for patients with urothelial carcinoma?

The approval of Pembrolizumab Enfortumab therapy as a first-line treatment opens new avenues for patient care, particularly for those eligible for cisplatin-based regimens. However, the economic implications of its high costs and selective effectiveness raise pressing questions about healthcare accessibility.

Curious about the balance between clinical benefits and economic realities in cancer treatment? Click to explore the full article!

#SyenzaNews #HealthEconomics #oncology #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.